232 related articles for article (PubMed ID: 21501485)
1. Pharmacologic disruption of Polycomb Repressive Complex 2 inhibits tumorigenicity and tumor progression in prostate cancer.
Crea F; Hurt EM; Mathews LA; Cabarcas SM; Sun L; Marquez VE; Danesi R; Farrar WL
Mol Cancer; 2011 Apr; 10():40. PubMed ID: 21501485
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.
Tan J; Yang X; Zhuang L; Jiang X; Chen W; Lee PL; Karuturi RK; Tan PB; Liu ET; Yu Q
Genes Dev; 2007 May; 21(9):1050-63. PubMed ID: 17437993
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
4. The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML.
Zhou J; Bi C; Cheong LL; Mahara S; Liu SC; Tay KG; Koh TL; Yu Q; Chng WJ
Blood; 2011 Sep; 118(10):2830-9. PubMed ID: 21734239
[TBL] [Abstract][Full Text] [Related]
5. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
6. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.
Zhang L; Jiao M; Li L; Wu D; Wu K; Li X; Zhu G; Dang Q; Wang X; Hsieh JT; He D
J Cancer Res Clin Oncol; 2012 Apr; 138(4):675-86. PubMed ID: 22237455
[TBL] [Abstract][Full Text] [Related]
7. Polycomb repressor complex-2 is a novel target for mesothelioma therapy.
Kemp CD; Rao M; Xi S; Inchauste S; Mani H; Fetsch P; Filie A; Zhang M; Hong JA; Walker RL; Zhu YJ; Ripley RT; Mathur A; Liu F; Yang M; Meltzer PA; Marquez VE; De Rienzo A; Bueno R; Schrump DS
Clin Cancer Res; 2012 Jan; 18(1):77-90. PubMed ID: 22028491
[TBL] [Abstract][Full Text] [Related]
8. 3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.
Mayr C; Wagner A; Stoecklinger A; Jakab M; Illig R; Berr F; Pichler M; Di Fazio P; Ocker M; Neureiter D; Kiesslich T
Anticancer Res; 2015 Sep; 35(9):4697-705. PubMed ID: 26254359
[TBL] [Abstract][Full Text] [Related]
9. Polycomb genes and cancer: time for clinical application?
Crea F; Paolicchi E; Marquez VE; Danesi R
Crit Rev Oncol Hematol; 2012 Aug; 83(2):184-93. PubMed ID: 22112692
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
11. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
12. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer.
Berezovska OP; Glinskii AB; Yang Z; Li XM; Hoffman RM; Glinsky GV
Cell Cycle; 2006 Aug; 5(16):1886-901. PubMed ID: 16963837
[TBL] [Abstract][Full Text] [Related]
13. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer.
Bansal N; Bartucci M; Yusuff S; Davis S; Flaherty K; Huselid E; Patrizii M; Jones D; Cao L; Sydorenko N; Moon YC; Zhong H; Medina DJ; Kerrigan J; Stein MN; Kim IY; Davis TW; DiPaola RS; Bertino JR; Sabaawy HE
Clin Cancer Res; 2016 Dec; 22(24):6176-6191. PubMed ID: 27307599
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Iannelli F; Roca MS; Lombardi R; Ciardiello C; Grumetti L; De Rienzo S; Moccia T; Vitagliano C; Sorice A; Costantini S; Milone MR; Pucci B; Leone A; Di Gennaro E; Mancini R; Ciliberto G; Bruzzese F; Budillon A
J Exp Clin Cancer Res; 2020 Oct; 39(1):213. PubMed ID: 33032653
[TBL] [Abstract][Full Text] [Related]
15. DNMT1 Regulates Epithelial-Mesenchymal Transition and Cancer Stem Cells, Which Promotes Prostate Cancer Metastasis.
Lee E; Wang J; Yumoto K; Jung Y; Cackowski FC; Decker AM; Li Y; Franceschi RT; Pienta KJ; Taichman RS
Neoplasia; 2016 Sep; 18(9):553-66. PubMed ID: 27659015
[TBL] [Abstract][Full Text] [Related]
16. FOXC1, a target of polycomb, inhibits metastasis of breast cancer cells.
Du J; Li L; Ou Z; Kong C; Zhang Y; Dong Z; Zhu S; Jiang H; Shao Z; Huang B; Lu J
Breast Cancer Res Treat; 2012 Jan; 131(1):65-73. PubMed ID: 21465172
[TBL] [Abstract][Full Text] [Related]
17. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma.
Anestopoulos I; Sfakianos AP; Franco R; Chlichlia K; Panayiotidis MI; Kroll DJ; Pappa A
Molecules; 2016 Dec; 22(1):. PubMed ID: 28042859
[TBL] [Abstract][Full Text] [Related]
18. Polycomb repressive complex 2 is required for MLL-AF9 leukemia.
Neff T; Sinha AU; Kluk MJ; Zhu N; Khattab MH; Stein L; Xie H; Orkin SH; Armstrong SA
Proc Natl Acad Sci U S A; 2012 Mar; 109(13):5028-33. PubMed ID: 22396593
[TBL] [Abstract][Full Text] [Related]
19. Activation of EZH2 and SUZ12 Regulated by E2F1 Predicts the Disease Progression and Aggressive Characteristics of Bladder Cancer.
Lee SR; Roh YG; Kim SK; Lee JS; Seol SY; Lee HH; Kim WT; Kim WJ; Heo J; Cha HJ; Kang TH; Chung JW; Chu IS; Leem SH
Clin Cancer Res; 2015 Dec; 21(23):5391-403. PubMed ID: 26268246
[TBL] [Abstract][Full Text] [Related]
20. RNAi-mediated silencing of Myc transcription inhibits stem-like cell maintenance and tumorigenicity in prostate cancer.
Civenni G; Malek A; Albino D; Garcia-Escudero R; Napoli S; Di Marco S; Pinton S; Sarti M; Carbone GM; Catapano CV
Cancer Res; 2013 Nov; 73(22):6816-27. PubMed ID: 24063893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]